Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors to attack and eradicate cancer cells. The company is headquartered in Paris, France. Show more

8, RUE DE LA CROIX JARRY, PARIS, FRANCE, 75013, Paris, 75013, USA

https://www.cellectis.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

342.4M

52 Wk Range

$2.35 - $5.48

Previous Close

$3.35

Open

$3.29

Volume

9,821

Day Range

$3.10 - $3.50

Enterprise Value

281.5M

Cash

35.59M

Avg Qtr Burn

-14.28M

Insider Ownership

0.00%

Institutional Own.

15.36%

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
UCART22 Details Relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Cema-Cel (UCART19) (Anti-CD19 Car-T) Details Cancer, Large B-Cell Lymphoma	Phase 2 Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IOV-4001 (PD-1 Inactivated TIL) Details Advanced Melanoma And Non-Small Cell Lung Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
UCART123 Details Cancer, Relapsed/refractory acute myeloid leukemia	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
UCART20x22 Details Cancer, Non-Hodgkin lymphoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ALLO-501 Details Non-Hodgkin lymphoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ALLO-715 Details Cancer, Multiple myeloma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
UCARTCS1 Details Cancer, Multiple myeloma, Menkes Disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
UCART19 (anti-CD19) Details Cancer, Multiple myeloma, Acute lymphoblastic leukemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.